GRAIL Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
2.7%projected annual EPS growth
Analyst Coverage
8analysts covering
FY Revenue (est.)
$181Mnext fiscal year
FY EPS (est.)
-$7.68next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 11 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Galleri Test Volume Quarterly56KTarget: Continued volume expansion through digital health platforms and EHR integrations
Quarterly Total Revenue Quarterly40.8MTarget: Sustained double-digit year-over-year growth
Cash Runway and Liquidity Quarterly823.1MTarget: Maintain sufficient cash reserves to fund operations into late 2028
Watch Items
- FDA Premarket Approval (PMA) Review for GalleriTrigger: FDA decision on the PMA application submitted in January 2026Action: Monitor regulatory communications, advisory committee meetings, and final approval timelines.
- NHS-Galleri Trial Long-term Follow-up and Reimbursement DecisionsTrigger: Presentation of full clinical utility data and subsequent UK National Health Service coverage decisionsAction: Evaluate clinical data updates and policy shifts regarding population-scale screening coverage.
- Securities Class Action Litigation (Robbins v. GRAIL, Inc.)Trigger: August 4, 2026 lead plaintiff deadline and subsequent court rulings on motions to dismissAction: Assess potential financial liabilities, legal costs, and impacts on management focus.
Research as of 19 Jun 2026